GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » Inventories, Raw Materials & Components

Kancera AB (OSTO:KAN) Inventories, Raw Materials & Components : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Kancera AB Inventories, Raw Materials & Components?

Kancera AB's inventories, raw materials & components for the quarter that ended in Dec. 2024 was kr0.00 Mil.


Kancera AB Inventories, Raw Materials & Components Historical Data

The historical data trend for Kancera AB's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kancera AB Inventories, Raw Materials & Components Chart

Kancera AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kancera AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Kancera AB Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Kancera AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kancera AB (OSTO:KAN) » Definitions » Inventories, Raw Materials & Components
Traded in Other Exchanges
N/A
Address
Karolinska Institutet Science Park, Banvaktsvagen 22, Solna, SWE, 171 48
Kancera AB develops drugs that counteract damage in acute and chronic inflammation. The fractalkin blockers KAND567 and KAND145 are developed to effectively counteract hyperinflamation in various disease states and thereby protect vital organs in conjunction with myocardial infarction and severe viral infections. Kancera is planning two phase II clinical trials, in covid-19 and in cardiac patients. The company conducts research and development within the Karolinska Institute Science Park in Stockholm.

Kancera AB Headlines

No Headlines